Rational clinical trial design for antibody mediated renal allograft injury

Frontiers in Bioscience - Landmark

Volumn 20, Issue 4, 2015, Pages 743-762

  Sandal, Shaifali ^a   Zand, Martin S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alloantibody; Antibody mediated rejection; Apheresis; B cells; Kidney transplant; Review

Indexed keywords

ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN;

B LYMPHOCYTE; CELL SEPARATION; CLINICAL TRIAL (TOPIC); GRAFT REJECTION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; METHODOLOGY;

ANTIBODIES; B-LYMPHOCYTES; CELL SEPARATION; CLINICAL TRIALS AS TOPIC; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; RESEARCH DESIGN;

EID: 84918829965     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4334     Document Type: Review

References (110)

1. B. J. Nankivell and S. I. Alexander: Rejection of the kidney allograft. N Engl J Med, 363(15), 1451-62 (2010) DOI: 10.1056/NEJMra0902927
2. B. Sis, M. Mengel, M. Haas, R. B. Colvin, P. F. Halloran, L. C. Racusen, K. Solez, W. M. Baldwin, 3rd, E. R. Bracamonte, V. Broecker, F. Cosio, A. J. Demetris, C. Drachenberg, G. Einecke, J. Gloor, D. Glotz, E. Kraus, C. Legendre, H. Liapis, R. B. Mannon, B. J. Nankivell, V. Nickeleit, J. C. Papadimitriou, P. Randhawa, H. Regele, K. Renaudin, E. R. Rodriguez, D. Seron, S. Seshan, M. Suthanthiran, B. A. Wasowska, A. Zachary and A. Zeevi: Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant, 10(3), 464-71 (2010) DOI: 10.1111/j.1600-6143.2009.02987.x
3. D. Dragun, A. Philippe and R. Catar: Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant, 17(4), 440-5 (2012) DOI: 10.1097/MOT.0b013e328355f12b
4. L. Luo, Z. Li, W. Wu, G. Luo, C. Xu, Z. Sun and H. Mei: Role of MICA antibodies in solid organ transplantation. Clin Transplant (2013)
5. M. Sapak, S. Chrenova, J. Tirpakova, Z. Zilinska, V. Durmanova, I. Shawkatova, V. Jakus, D. Kuba and M. Buc: Donor non-specific MICA antibodies in renal transplant recipients. Immunobiology (2013)
6. R. B. Colvin: Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol, 18(4), 1046-56 (2007) DOI: 10.1681/ASN.2007010073
7. C. B. Drachenberg and J. C. Papadimitriou: Endothelial Injury in Renal Antibody-Mediated Allograft Rejection: A Schematic View Based on Pathogenesis. Transplantation (2013) DOI: 10.1097/TP.0b013e31827e6b45
8. H. H. Kuo, C. N. Morrell and W. M. Baldwin, 3rd: Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol, 73(12), 1233-8 (2012) DOI: 10.1016/j.humimm.2012.06.011
9. M. D. Stegall, M. F. Chedid and L. D. Cornell: The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol, 8(11), 670-8 (2012) DOI: 10.1038/nrneph.2012.212
10. M. Haas: Pathologic features of antibodymediated rejection in renal allografts: an expanding spectrum. Curr Opin Nephrol Hypertens, 21(3), 264-71 (2012) DOI: 10.1097/MNH.0b013e3283520efa
11. L. G. Hidalgo, B. Sis, J. Sellares, P. M. Campbell, M. Mengel, G. Einecke, J. Chang and P. F. Halloran: NK cell transcripts and NK cells in kidney biopsies from patients with donorspecific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant, 10(8), 1812-22 (2010) DOI: 10.1111/j.1600-6143.2010.03201.x
12. Y. Yamaguchi: Reviews on mysterious vascular endothelial cells in renal allografts. Clin Transplant, 26 Suppl 24, 13-9 (2012). DOI: 10.1111/j.1399-0012.2012.01675.x
13. J. C. Papadimitriou, C. B. Drachenberg, E. Ramos, D. Kukuruga, D. K. Klassen, R. Ugarte, J. Nogueira, C. Cangro, M. R. Weir and A. Haririan: Antibody-Mediated Allograft Rejection: Morphologic Spectrum and Serologic Correlations in Surveillance and for Cause Biopsies. Transplantation (2012)
14. C. G. Vinuesa, M. A. Linterman, C. C. Goodnow and K. L. Randall: T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev, 237(1), 72-89 (2010) DOI: 10.1111/j.1600-065X.2010.00937.x
15. M. R. Clatworthy: Targeting B cells and antibody in transplantation. Am J Transplant, 11(7), 1359-67 (2011) DOI: 10.1111/j.1600-6143.2011.03554.x
16. C. Lawrence, M. Willicombe, P. A. Brookes, E. Santos-Nunez, R. Bajaj, T. Cook, C. Roufosse, D. Taube and A. N. Warrens: Preformed Complement-Activating Low-Level Donor-Specific Antibody Predicts Early Antibody-Mediated Rejection in Renal Allografts. Transplantation (2012)
17. M. Mengel, B. Sis, M. Haas, R. B. Colvin, P. F. Halloran, L. C. Racusen, K. Solez, L. Cendales, A. J. Demetris, C. B. Drachenberg, C. F. Farver, E. R. Rodriguez, W. D. Wallace, D. Glotz and c. Banff meeting report writing: Banff 2011 Meeting report: new concepts in antibodymediated rejection. Am J Transplant, 12(3), 563-70 (2012) DOI: 10.1111/j.1600-6143.2011.03926.x
18. L. C. Racusen, R. B. Colvin, K. Solez, M. J. Mihatsch, P. F. Halloran, P. M. Campbell, M. J. Cecka, J. P. Cosyns, A. J. Demetris, M. C. Fishbein, A. Fogo, P. Furness, I. W. Gibson, D. Glotz, P. Hayry, L. Hunsickern, M. Kashgarian, R. Kerman, A. J. Magil, R. Montgomery, K. Morozumi, V. Nickeleit, P. Randhawa, H. Regele, D. Seron, S. Seshan, S. Sund and K. Trpkov: Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant, 3(6), 708-14 (2003) DOI: 10.1034/j.1600-6143.2003.00072.x
19. C. Ponticelli: The mechanisms of acute transplant rejection revisited. J Nephrol, 25(2), 150-8 (2012) DOI: 10.5.301/jn.5000048
20. M. Haas: C4d-negative antibodymediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol, 75(4), 271-8 (2011) DOI: 10.5414/CNP75271
21. B. Sis and P. F. Halloran: Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibodymediated rejection. Curr Opin Organ Transplant, 15(1), 42-8 (2010) DOI: 10.1097/MOT.0b013e3283352a50
22. N. Singh, Q. Sun, T. Nadasdy, P. Adams, N. R. Dipaola, T. Pesavento, H. Winters, A. Satoskar, Z. Yu, M. Henry, G. A. Hadley and R. P. Pelletier: The pathogenesis of acute allograft dysfunction in desensitized renal transplant recipients. Clin Transplant, 26(4), E402-11 (2012) DOI: 10.1111/j.1399-0012.2012.01684.x
23. H. Bian, P. E. Harris, A. Mulder and E. F. Reed: Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol, 53(1), 90-7 (1997) DOI: 10.1016/S0198-8859(96)00272-8
24. M. Haas: Transplant glomerulopathy: it's not always about chronic rejection. Kidney Int, 80(8), 801-3 (2011) DOI: 10.1038/ki.2011.192
25. F. M. Heinemann, I. Roth, V. Rebmann, M. L. Arnold, O. Witzke, B. Wilde, B. M. Spriewald and H. Grosse-Wilde: Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol, 68(6), 500-6 (2007) DOI: 10.1016/j.humimm.2007.02.007
26. S. Joyce, M. W. Flye and T. Mohanakumar: Characterization of kidney cell-specific, non-major histocompatibility complex alloantigen using antibodies eluted from rejected human renal allografts. Transplantation, 46(3), 362-9 (1988) DOI: 10.1097/00007890-198809000-00006
27. T. Mohanakumar, M. Phibbs, J. Haar, G. Mendez, A. M. Kaplan and H. M. Lee: Alloantibodies eluted from rejected human renal allografts: reactivity to primary kidney cells in culture. Transplant Proc, 12(3 Suppl 1), 65-68 (1980)
28. B. Sis, G. S. Jhangri, S. Bunnag, K. Allanach, B. Kaplan and P. F. Halloran: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant, 9(10), 2312-23 (2009 DOI: 10.1111/j.1600-6143.2009.02761.x
29. M. Toyoda, S. Ge, E. Suviolahti, P. Pichurin, B. Shin, A. Pao, A. Vo, N. Deer, A. Aguiluz, A. Karasyov and S. C. Jordan: IFNgamma production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transpl Immunol, 26(2-3), 107-12 (2012) DOI: 10.1016/j.trim.2011.11.001
30. A. Kobayashi, T. Takahashi, S. Horita, I. Yamamoto, H. Yamamoto, K. Tanabe, Y. Yamaguchi and T. Hosoya: Clinicopathological impacts of activated transcription factor c-Jun in peritubular capillary endothelial cells in chronic antibodymediated rejection after kidney transplantation. Clin Nephrol, 77(1), 32-9 (2012) DOI: 10.5414/CN107246
31. G. S. Hill, D. Nochy, P. Bruneval, J. P. Duong van Huyen, D. Glotz, C. Suberbielle, J. Zuber, D. Anglicheau, J. P. Empana, C. Legendre and A. Loupy: Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol, 22(5), 975-83 (2011) DOI: 10.1681/ASN.2010070777
32. C. Lefaucheur, A. Loupy, D. Vernerey, J. P. Duong-Van-Huyen, C. Suberbielle, D. Anglicheau, J. Verine, T. Beuscart, D. Nochy, P. Bruneval, D. Charron, M. Delahousse, J. P. Empana, G. S. Hill, D. Glotz, C. Legendre and X. Jouven: Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012)
33. F. Nimmerjahn and J. V. Ravetch: Fcgamma receptors as regulators of immune responses. Nat Rev Immunol, 8(1), 34-47 (2008) DOI: 10.1038/nri2206
34. C. J. Callaghan, T. S. Win, R. Motallebzadeh, T. M. Conlon, M. Chhabra, I. Harper, S. Sivaganesh, E. M. Bolton, J. A. Bradley, R. J. Brownlie, K. G. Smith and G. J. Pettigrew: Regulation of allograft survival by inhibitory FcgammaRIIb signaling. J Immunol, 189(12), 5694-702 (2012) DOI: 10.4049/jimmunol.1202084
35. T. Rahman and L. Harper: Plasmapheresis in nephrology: an update. Curr Opin Nephrol Hypertens, 15(6), 603-9 (2006) DOI: 10.1097/01.mnh.0000247503.87162.15
36. C. D. Pusey and J. B. Levy: Plasmapheresis in immunologic renal disease. Blood Purif, 33(1-3), 190-8 (2012) DOI: 10.1159/000334155
37. R. Higgins, D. Lowe, M. Hathaway, F. T. Lam, H. Kashi, L. C. Tan, C. Imray, S. Fletcher, K. Chen, N. Krishnan, R. Hamer, D. Zehnder and D. Briggs: Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial,
38. N. H. Allen, P. Dyer, T. Geoghegan, K. Harris, H. A. Lee and M. Slapak: Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation, 35(5), 425-8 (1983) DOI: 10.1097/00007890-198305000-00006
39. D. Power, A. Nicholls, N. Muirhead, A. M. MacLeod, J. Engeset, G. R. Catta and N. Edward: Plasma exchange in acute renal allograft rejection: is a controlled trial really necessary? Transplantation, 32(2), 162-3 (1981) DOI: 10.1097/00007890-198108000-00018
40. J. P. Soulillou, C. Guyot, J. Guimbretiere, M. Girard, A. Ythier, J. D. Bignon, M. Hourmant and J. Guenel: Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron, 35(3), 158-62 (1983) DOI: 10.1159/000183067
41. P. N. Rocha, D. W. Butterly, A. Greenberg, D. N. Reddan, J. Tuttle-Newhall, B. H. Collins, P. C. Kuo, N. Reinsmoen, T. Fields, D. N. Howell and S. R. Smith: Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation, 75(9), 1490-5 (2003) DOI: 10.1097/01.TP.0000060252.57111.AC
42. A. M. Gomes, S. Pedroso, L. S. Martins, J. Malheiro, J. R. Viscayno, J. Santos, L. Dias, A. C. Henriques, A. M. Sarmento and A. Cabrita: Diagnosis and treatment of acute humoral kidney allograft rejection. Transplant Proc, 41(3), 855-8 (2009) DOI: 10.1016/j.transproceed.2009.01.062
43. R. A. Montgomery, A. A. Zachary, L. C. Racusen, M. S. Leffell, K. E. King, J. Burdick, W. R. Maley and L. E. Ratner: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation, 70(6), 887-95 (2000) DOI: 10.1097/00007890-200009270-00006
44. E. Siskind, M. Bhaskaran, F. Boctor, K. Shah and E. Molmenti: Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports. Int J Angiol, 21(2), 107-10 (2012) DOI: 10.1055/s-0032-1315622
45. A. A. Zachary, R. A. Montgomery, L. E. Ratner, M. Samaniego-Picota, M. Haas, D. Kopchaliiska and M. S. Leffell: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation, 76(10), 1519-25 (2003) DOI: 10.1097/01.TP.0000090868.88895.E0
46. M. J. Everly, J. J. Everly, B. Susskind, P. Brailey, L. J. Arend, R. R. Alloway, P. Roy-Chaudhury, A. Govil, G. Mogilishetty, A. H. Rike, M. Cardi, G. Wadih, A. Tevar and E. S. Woodle: Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation, 86(12), 1754-61 (2008) DOI: 10.1097/TP.0b013e318190af83
47. B. Sadaka, R. R. Alloway, A. R. Shields, N. M. Schmidt and E. S. Woodle: Proteasome inhibition for antibody-mediated allograft rejection. Semin Hematol, 49(3), 263-9 (2012) DOI: 10.1053/j.seminhematol.2012.04.008
48. E. S. Woodle, R. C. Walsh, R. R. Alloway, A. Girnita and P. Brailey: Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant, 15(6), 548-56 (2011)
49. O. Gungor, S. Sen, F. Kircelli, M. Yilmaz, B. Sarsik, M. Ozkahya, C. Hoscoskun, E. Ok and H. Toz: Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc, 43(3), 853-7 (2011) DOI: 10.1016/j.transproceed.2011.03.025
50. N. B. White, S. M. Greenstein, A. W. Cantafio, R. Schechner, D. Glicklich, P. McDonough, J. Pullman, K. Mohandas, F. Boctor, J. Uehlinger and V. Tellis: Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation, 78(5), 772-4 (2004) DOI: 10.1097/01.TP.0000128194.55934.48
51. C. M. Brown, K. A. Abraham, P. O'Kelly, P. J. Conlon and J. J. Walshe: Longterm experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc, 41(9), 3690-2 (2009) DOI: 10.1016/j.transproceed.2009.06.197
52. C. Morath, J. Beimler, G. Opelz, S. Scherer, J. Schmidt, S. Macher-Goeppinger, K. Klein, C. Sommerer, V. Schwenger, M. Zeier and C. Susal: Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int, 25(5), 506-17 (2012) DOI: 10.1111/j.1432-2277.2012.01447.x
53. C. Morath, L. E. Becker, A. Leo, J. Beimler, K. Klein, J. Seckinger, L. P. Kihm, P. Schemmer, S. Macher-Goeppinger, M. Wahrmann, G. A. Bohmig, G. Opelz, C. Susal, M. Zeier and V. Schwenger: ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation, 93(8), 827-34 (2012) DOI: 10.1097/TP.0b013e31824836ae
54. A. R. Biglarnia, B. Nilsson, K. Nilsson Ekdahl, G. Tufveson, T. Nilsson, E. Larsson and J. Wadstrom: Desensitization with antigen-specific immunoadsorption interferes with complement in ABOincompatible kidney transplantation. Transplantation, 93(1), 87-92 (2012) DOI: 10.1097/TP.0b013e31823bb689
55. G. A. Bohmig, M. Wahrmann, H. Regele, M. Exner, B. Robl, K. Derfler, T. Soliman, P. Bauer, M. Mullner and W. Druml: Immunoadsorption in severe C4dpositive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant, 7(1), 117-21 (2007) DOI: 10.1111/j.1600-6143.2006.01613.x
56. G. A. Bohmig, H. Regele, M. Exner, V. Derhartunian, J. Kletzmayr, M. D. Saemann, W. H. Horl, W. Druml and B. Watschinger: C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol, 12(11), 2482-9 (2001)
57. P. V. Valli, G. Puga Yung, T. Fehr, C. Schulz-Huotari, N. Kaup, T. Gungor, P. Ambuhl, M. Weber, U. Schanz, J. D. Seebach and G. Stussi: Changes of circulating antibody levels induced by ABO antibody adsorption for ABOincompatible kidney transplantation. Am J Transplant, 9(5), 1072-80 (2009) DOI: 10.1111/j.1600-6143.2009.02579.x
58. V. Schwenger and C. Morath: Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant, 25(8), 2407-13 (2010) DOI: 10.1093/ndt/gfq264
59. F. Eskandary, M. Wahrmann, P. Biesenbach, C. Sandurkov, F. Konig, E. Schwaiger, T. Perkmann, S. Kunig, K. Derfler, G. J. Zlabinger and G. A. Bohmig: ABO antibody and complement depletion by immunoadsorption combined with membrane filtration - a randomized, controlled, cross-over trial. Nephrol Dial Transplant (2013)
60. M. Belak, H. Borberg, C. Jimenez and K. Oette: Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci, 15(4), 419-22 (1994) DOI: 10.1016/0955-3886(94)90174-0
61. G. Tyden, G. Kumlien, H. Genberg, J. Sandberg, T. Lundgren and I. Fehrman: ABO incompatible kidney transplantations without splenectomy, using antigenspecific immunoadsorption and rituximab. Am J Transplant, 5(1), 145-8 (2005) DOI: 10.1111/j.1600-6143.2004.00653.x
62. S. A. Just, N. Marcussen, U. Sprogoe, P. Koefoed-Nielsen and C. Bistrup: Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigenspecific immunoadsorption. Nephrol Dial Transplant, 25(1), 310-3 (2010) DOI: 10.1093/ndt/gfp527
63. S. M. Ji, Z. H. Liu, J. S. Chen, G. Z. Sha, D. X. Ji and L. S. Li: Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. Transplant Proc, 38(10), 3459-63 (2006) DOI: 10.1016/j.transproceed.2006.10.151
64. M. Liu, S. M. Ji, Z. Tang, D. X. Ji, H. P. Chen, Z. H. Liu and L. S. Li: C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. Transplant Proc, 36(7), 2101-3 (2004) DOI: 10.1016/j.transproceed.2004.07.071
65. D. C. Roopenian, G. J. Christianson, T. J. Sproule, A. C. Brown, S. Akilesh, N. Jung, S. Petkova, L. Avanessian, E. Y. Choi, D. J. Shaffer, P. A. Eden and C. L. Anderson: The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol, 170(7), 3528-33 (2003) DOI: 10.4049/jimmunol.170.7.3528
66. S. C. Low and A. R. Mezo: Inhibitors of the FcRn:IgG protein-protein interaction. AAPS J, 11(3), 432-4 (2009) DOI: 10.1208/s12248-009-9120-5
67. D. C. Roopenian and S. Akilesh: FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 7(9), 715-25 (2007) DOI: 10.1038/nri2155
68. G. J. Christianson, V. Z. Sun, S. Akilesh, E. Pesavento, G. Proetzel and D. C. Roopenian: Monoclonal antibodies directed against human FcRn and their applications. MAbs, 4(2) (2012) DOI: 10.4161/mabs.4.2.19397
69. J. L. Scholz, J. E. Crowley, M. M. Tomayko, N. Steinel, P. J. O'Neill, W. J. Quinn, 3rd, R. Goenka, J. P. Miller, Y. H. Cho, V. Long, C. Ward, T. S. Migone, M. J. Shlomchik and M. P. Cancro: BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A, 105(40), 15517-22 (2008) DOI: 10.1073/pnas.0807841105
70. R. F. Parsons, K. Vivek, R. R. Redfield, 3rd, T. S. Migone, M. P. Cancro, A. Naji and H. Noorchashm: B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando), 24(4), 207-21 (2010) DOI: 10.1016/j.trre.2010.05.004
71. W. Stohl: Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep, 14(4), 303-9 (2012) DOI: 10.1007/s11926-012-0254-6
72. M. J. Benson, S. R. Dillon, E. Castigli, R. S. Geha, S. Xu, K. P. Lam and R. J. Noelle: Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol, 180(6), 3655-9 (2008) DOI: 10.4049/jimmunol.180.6.3655
73. V. Zarkhin, L. Li and M. M. Sarwal: BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation, 88(10), 1229-30 (2009) DOI: 10.1097/TP.0b013e3181bbba1a
74. N. S. Patel, P. K. Chatterjee, R. Di Paola, E. Mazzon, D. Britti, A. De Sarro, S. Cuzzocrea and C. Thiemermann: Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther, 312(3), 1170-8 (2005) DOI: 10.1124/jpet.104.078659
75. D. O. Dahle, G. Mjoen, B. Oqvist, H. Scharnagl, G. Weihrauch, T. Grammer, W. Marz, S. Abedini, G. E. Norby, I. Holme, B. Fellstrom, A. Jardine and H. Holdaas: Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant, 26(11), 3756-61 (2011) DOI: 10.1093/ndt/gfr163
76. K. Muhammad, P. Roll, T. Seibold, S. Kleinert, H. Einsele, T. Dorner and H. P. Tony: Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis, 70(8), 1507-10 (2011) DOI: 10.1136/ard.2010.141325
77. P. Roll, K. Muhammad, M. Schumann, S. Kleinert, H. Einsele, T. Dorner and H. P. Tony: In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum, 63(5), 1255-64 (2011) DOI: 10.1002/art.30242
78. G. Wu, N. Chai, I. Kim, A. S. Klein and S. C. Jordan: Monoclonal anti-interleukin-6 receptor antibody attenuates donorspecific antibody responses in a mouse model of allosensitization. Transpl Immunol, 28(2-3), 138-43 (2013) DOI: 10.1016/j.trim.2013.03.003
79. J. Waiser, K. Budde, M. Schutz, L. Liefeldt, B. Rudolph, C. Schonemann, H. H. Neumayer and N. Lachmann: Comparison between bortezomib and rituximab in the treatment of antibodymediated renal allograft rejection. Nephrol Dial Transplant, 27(3), 1246-51 (2012) DOI: 10.1093/ndt/gfr465
80. M. Schiffer and J. T. Kielstein: ABOincompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier. Korean J Hematol, 46(3), 164-8 (2011) DOI: 10.5045/kjh.2011.46.3.164
81. Z. Kaposztas, H. Podder, S. Mauiyyedi, O. Illoh, R. Kerman, M. Reyes, V. Pollard and B. D. Kahan: Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant, 23(1), 63-73 (2009) DOI: 10.1111/j.1399-0012.2008.00902.x
82. Y. G. Zhao, B. Y. Shi, Y. Y. Qian, H. W. Bai, L. Xiao and X. Y. He: Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis. Int Urol Nephrol (2013)
83. B. Tanriover, S. E. Wright, S. V. Foster, K. S. Roush, J. A. Castillo-Lugo, K. Fa, F. L. Levy and A. Mejia: High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc, 40(10), 3393-6 (2008) DOI: 10.1016/j.transproceed.2008.08.131
84. T. Fehr, B. Rusi, A. Fischer, H. Hopfer, R. P. Wuthrich and A. Gaspert: Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation, 87(12), 1837-41 (2009) DOI: 10.1097/TP.0b013e3181a6bac5
85. H. Billing, S. Rieger, J. Ovens, C. Susal, A. Melk, R. Waldherr, G. Opelz and B. Tonshoff: Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation, 86(9), 1214-21 (2008) DOI: 10.1097/TP.0b013e3181880b35
86. N. Kohei, T. Hirai, K. Omoto, H. Ishida and K. Tanabe: Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant, 12(2), 469-76 (2012) DOI: 10.1111/j.1600-6143.2011.03830.x
87. H. E. Mei, S. Schmidt and T. Dorner: Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther, 14 Suppl 5, S1 (2012) DOI: 10.1186/ar3909
88. D. J. DiLillo, R. Griffiths, S. V. Seshan, C. M. Magro, P. Ruiz, T. M. Coffman and T. F. Tedder: B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol, 186(4), 2643-54 (2011) DOI: 10.4049/jimmunol.1002983
89. M. J. Everly and P. I. Terasaki: The state of therapy for removal of alloantibody producing plasma cells in transplantation. Semin Immunol, 24(2), 143-7 (2012) DOI: 10.1016/j.smim.2011.08.014
90. N. Schmidt, R. R. Alloway, R. C. Walsh, B. Sadaka, A. R. Shields, A. L. Girnita, D. J. Hanseman and E. S. Woodle: Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation, 94(4), 352-61 (2012) DOI: 10.1097/TP.0b013e318257acf6
91. K. M. Kortuem and A. K. Stewart: Carfilzomib. Blood, 121(6), 893-7 (2013) DOI: 10.1182/blood-2012-10-459883
92. B. S. Husberg: The influence of cyclophosphamide on the rejection of allogenic rat kidney transplants. An in vitro study of cell-bound and antibodymediated immunity. Clin Exp Immunol, 10(4), 697-711 (1972)
93. S. Cang, N. Mukhi, K. Wang and D. Liu: Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol, 5, 64 (2012) DOI: 10.1186/1756-8722-5-64
94. J. E. Locke, A. A. Zachary, M. Haas, J. K. Melancon, D. S. Warren, C. E. Simpkins, D. L. Segev and R. A. Montgomery: The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant, 7(4), 842-6 (2007) DOI: 10.1111/j.1600-6143.2006.01709.x
95. I. Tzvetanov, M. Spaggiari, H. Jeon, R. G. Roca, C. Bhati, J. Oberholzer and E. Benedetti: The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation. Transplant Proc, 44(5), 1254-8 (2012) DOI: 10.1016/j.transproceed.2012.01.109
96. M. Latzko, S. Jasra, S. Akbar, H. Sun and S. Palekar: Laparoscopic splenectomy to salvage renal transplants from severe acute antibody-mediated rejection. Case Rep Transplant, 2012, 253173 (2012)
97. B. Kaplan, T. Jie, R. Diana, J. Renz, A. Whinery, N. Stubbs, E. Bracamonte, C. Spier, P. Schubart, H. Rilo and R. Gruessner: Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant, 10(5), 1316-20 (2010) DOI: 10.1111/j.1600-6143.2010.03067.x
98. M. D. Stegall, T. Diwan, S. Raghavaiah, L. D. Cornell, J. Burns, P. G. Dean, F. G. Cosio, M. J. Gandhi, W. Kremers and J. M. Gloor: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant, 11(11), 2405-13 (2011) DOI: 10.1111/j.1600-6143.2011.03757.x
99. Z. A. Stewart, T. E. Collins, A. J. Schlueter, T. I. Raife, D. G. Holanda, R. Nair, A. I. Reed and C. P. Thomas: Case Report: Eculizumab Rescue of Severe Accelerated Antibody-Mediated Rejection After ABO-Incompatible Kidney Transplant. Transplant Proc, 44(10), 3033-6 (2012) DOI: 10.1016/j.transproceed.2012.03.053
100. E. S. Woodle and W. M. Baldwin, 3rd: Of mice and men: terminal complement inhibition with anti-C5 monoclonal antibodies. Am J Transplant, 11(11), 2277-8 (2011) DOI: 10.1111/j.1600-6143.2011.03760.x
101. S. Chen Song, S. Zhong, Y. Xiang, J. H. Li, H. Guo, W. Y. Wang, Y. L. Xiong, X. C. Li, S. Chen Shi, X. P. Chen and G. Chen: Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant, 11(10), 2057-66 (2011) DOI: 10.1111/j.1600-6143.2011.03646.x
102. S. C. Jordan, M. Toyoda and A. A. Vo: Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol, 7(3), 341-8 (2011) DOI: 10.1586/eci.11.10
103. S. C. Jordan, M. Toyoda, J. Kahwaji and A. A. Vo: Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant, 11(2), 196-202 (2011) DOI: 10.1111/j.1600-6143.2010.03400.x
104. S. C. Jordan, A. W. Quartel, L. S. Czer, D. Admon, G. Chen, M. C. Fishbein, J. Schwieger, R. W. Steiner, C. Davis and D. B. Tyan: Posttransplant therapy using highdose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation, 66(6), 800-5 (1998) DOI: 10.1097/00007890-199809270-00017
105. S. C. Jordan, M. Toyoda and A. A. Vo: Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation, 88(1), 1-6 (2009) DOI: 10.1097/TP.0b013e3181a9e89a
106. S. C. Jordan, A. A. Vo, M. Toyoda, D. Tyan and C. C. Nast: Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant, 9(2), 155-61 (2005) DOI: 10.1111/j.1399-3046.2005.00256.x
107. K. Baker, S. W. Qiao, T. Kuo, K. Kobayashi, M. Yoshida, W. I. Lencer and R. S. Blumberg: Immune and nonimmune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol, 31(2), 223-36 (2009) DOI: 10.1007/s00281-009-0160-9
108. J. Kim, W. L. Hayton, J. M. Robinson and C. L. Anderson: Kinetics of FcRnmediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol, 122(2), 146-55 (2007) DOI: 10.1016/j.clim.2006.09.001
109. C. Lefaucheur, D. Nochy, J. Andrade, J. Verine, C. Gautreau, D. Charron, G. S. Hill, D. Glotz and C. Suberbielle- Boissel: Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant, 9(5), 1099-107 (2009) DOI: 10.1111/j.1600-6143.2009.02591.x
110. T. S. Diwan, S. Raghavaiah, J. M. Burns, W. K. Kremers, J. M. Gloor and M. D. Stegall: The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation, 91(5), 536-41 (2011) DOI: 10.1097/TP.0b013e3182081333